Johnson Pharmacare (532154) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
13 Aug, 2026Executive summary
Unaudited financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board on August 13, 2026.
Financial highlights
Total income from operations for the quarter was ₹158.10 lakhs, unchanged year-over-year.
Net loss before tax and exceptional items was ₹110.31 lakhs, compared to a net loss of ₹5.34 lakhs in the same quarter last year.
After accounting for exceptional items, net loss before tax was ₹110.31 lakhs, versus ₹5.34 lakhs loss year-over-year.
Earnings per share (basic and diluted) for the quarter stood at ₹(0.02), compared to ₹(0.00) in the same quarter last year.
Key financial ratios and metrics
Paid-up equity share capital remained at ₹5,500.00 lakhs.
EPS (basic and diluted) for the quarter was ₹(0.02), compared to ₹(0.00) in the prior year quarter.
Latest events from Johnson Pharmacare
- FY26 saw a sharp net loss, negative cash flows, and major doubts about financial viability.532154
Q4 25/26 - New auditor and independent director appointed, with all regulatory confirmations in place.532154Q3 25/26
- No revenue and continued net losses reported for the quarter ended September 30, 2025.532154Q2 25/26
- Net loss narrowed for Q2 and H1 FY25, with negligible revenue and stable equity.532154Q2 24/25
- Net loss of ₹3.99 lakhs on revenue of ₹3.99 lakhs reported for Q1 FY25.532154Q1 24/25
- Net loss widened to Rs. 58.38 lakhs in FY25, driven by a SEBI penalty and no revenue.532154Q4 24/25
- Net loss increased to Rs. 5.34 lakhs for Q1 FY26 as income declined and expenses rose.532154Q1 25/26
- Q3 FY25 saw flat revenue and a net loss, with auditors raising no concerns.532154Q3 24/25